Experienced in Pernicious Anemia

Dr. Nebu Koshy

Oncology | Hematology
3410 Worth Street, Suite 300, 
Dallas, TX 
Offers Telehealth
23 Years of Experience
Experienced in Pernicious Anemia
3410 Worth Street, Suite 300, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nebu Koshy is a Hematologist and an Oncologist in Dallas, Texas. Dr. Koshy has been practicing medicine for over 23 years and is rated as an Experienced provider by MediFind in the treatment of Pernicious Anemia. His top areas of expertise are Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Aplastic Anemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pernicious Anemia.

Graduate Institution
Jawaharlal Nehru Medical College, 2002
Residency
Internal Medicine, Louisiana State University In Shreveport
Specialties
Oncology
Hematology
Licenses
Internal Medicine in LA
Fellowships
Hematology/Oncology, Louisiana State University In Shreveport
Hematology/Oncology, LA State Univ at Shreveport School of Medicine
Bone Marrow/Stem Cell Transplant, Weill Medical College of Cornell University
Bone Marrow and Stem Cell Transplant, Weill Cornell Medicine
Hospital Affiliations
Baylor Scott & White Heart & Vascular Hospital - Dallas
Baylor University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
3410 Worth Street, Suite 300, Dallas, TX 75246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

16 Total Publications

Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 19, 2024
Similar Doctors
Advanced in Pernicious Anemia
Dr. Lakshmi P. Kannan
Oncology | Hematology
Advanced in Pernicious Anemia
Dr. Lakshmi P. Kannan
Oncology | Hematology

Texas Oncology, P.A.

Dallas, TX 
 (10.1 miles away)
972-449-0540
Experience:
30+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lakshmi Kannan is a Hematologist and an Oncologist in Dallas, Texas. Dr. Kannan has been practicing medicine for over 30 years and is rated as an Advanced provider by MediFind in the treatment of Pernicious Anemia. Her top areas of expertise are Childhood Iron Deficiency Anemia, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Lung Cancer.

Advanced in Pernicious Anemia
Dr. Revathi Angitapalli
Oncology | Hematology
Advanced in Pernicious Anemia
Dr. Revathi Angitapalli
Oncology | Hematology

The Center For Cancer And Blood Disorders

515 West Mayfield Road, Suite 102, 
Arlington, TX 
 (19.1 miles away)
817-960-6100
Experience:
25+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Revathi Angitapalli is a Hematologist and an Oncologist in Arlington, Texas. Dr. Angitapalli has been practicing medicine for over 25 years and is rated as a Distinguished provider by MediFind in the treatment of Pernicious Anemia. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma.

Experienced in Pernicious Anemia
Dr. Ashwani K. Agarwal
Oncology
Experienced in Pernicious Anemia
Dr. Ashwani K. Agarwal
Oncology

Texas Oncology, P.A.

Dallas, TX 
 (10.1 miles away)
972-449-0540
Experience:
42+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ashwani Agarwal is an Oncologist in Dallas, Texas. Dr. Agarwal has been practicing medicine for over 42 years and is rated as a Distinguished provider by MediFind in the treatment of Pernicious Anemia. His top areas of expertise are Familial Colorectal Cancer, Anemia, Colorectal Cancer, and Childhood Iron Deficiency Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Koshy's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile